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The liver has a unique regenerative response towards injuries. After removal of the harmful 
source, the mass, architecture and function of liver tissue can be entirely restored. However, 
in chronic conditions when the injury is long-lasting and persistent, the healing response shifts 
to fibrogenesis where scar-forming connective tissue gradually disrupts the liver function 
leading to cirrhosis and increasing the risk for liver cancer. Cirrhosis, as the terminal stage of 
progressive liver fibrosis, is the 12th most common cause of death worldwide. Over a million 
patients die from cirrhosis every year, which is 2.2% of all deaths annually [1,2]. Liver fibrosis 
develops in response to a variety of triggers, such as viral hepatitis, excess alcohol consumption, 
non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, hemochromatosis, as well 
as hereditary diseases, including progressive familial intrahepatic cholestasis (PFIC), Wilson’s 
disease, haemochromatosis and α1-anti-trypsin deficiency. In the final stages of cirrhosis, the 
liver may fail with systemic complications, such as portal hypertension-induced variceal bleeding, 
ascites, hepatic encephalopathy, bacterial infection and often hepatocellular carcinoma (HCC). 
Although there is no medicine to directly target (advanced) fibrosis, accumulating clinical 
and experimental evidence show that liver fibrosis can be halted and even reversed using 
combination therapies [3–6]. The common ground for all therapeutic approaches consists of 
attenuating pathological mechanisms and simultaneously promoting liver regeneration.
Liver fibrosis begins with deposition of connective tissue (components of the extracellular 
matrix (ECM), particularly collagen I, collagen III and fibronectin) in and around inflamed 
or damaged areas [7]. The source of the abnormal ECM are myofibroblasts. Exposure to a 
variety of triggers, including inflammatory molecules and oxidative stress, myofibroblasts, in 
particular Hepatic Stellate Cells (HSC), undergo cell-intrinsic changes to become ‘activated’. 
Activated myofibroblasts are migratory, contractile and proliferative and mostly derive from 
two mesenchymal origins, Hepatic Stellate Cells and portal myofibroblasts. Extracellular signals 
from other cells, such as macrophages, hepatocytes, liver sinusoidal endothelial cells, natural 
killer (T) cells, platelets and B cells, promote HSC activation. The external stimuli from other 
cells are mainly paracrine factors, such as platelet-derived growth factor (PDGF), transforming 
growth factor β (TGFβ) and other growth factors together with cytokines and chemokines [8]. 
The function and morphology of HSC-derived myofibroblasts are very similar to those that 
originate from portal myofibroblast. Thus, the therapeutic strategies that aim to block the 
trans-differentiation from the mesenchymal phenotype to the fibroblast phenotype are similar 
and will target both types. However, HSCs appear to be the primary target for direct treatment 
of liver fibrosis, as they are the  major source of myofibroblasts (over 80%) in rodent models of 
liver fibrosis, including chronic CCl4 exposure, bile duct ligation, the 3,5-diethoxycarbonyl-1,4- 




Quiescent Hepatic Stellate Cells (qHSCs)
In healthy conditions, HSCs are in a ‘quiescent’ state populating about 15% of all cells in the liver. 
qHSCs are located in the subendothelial space of Disse between hepatocytes and sinusoids that 
carry nutrient- and oxygen-rich blood to the hepatocytes [10,11]. HSCs are relatively small in 
size compared to hepatocytes and characterized by large cytoplasmic lipid droplets. The HSC 
lipid droplets are specialized organelles for storage and metabolism of retinoids (e.g. vitamin A) 
and store about 80-90% of total retinoids of the liver and about 50-80% of total retinoids in the 
body. HSCs are responsible for maintaining stable levels of circulating retinyl in blood at around 
2 µmol/L in humans and 1-1.5 µmol/L in rodents[1]. Most retinoids in the cytoplasmic droplets 
are stored in the form of retinyl esters, predominantly as retinyl palmitate. The composition 
and size of these lipid droplets are dependent on dietary intake. Besides retinoids, other lipids, 
such as triglycerides, phospholipids, cholesterol and free fatty acids, are abundantly deposited 
in HSC lipid droplets [11,12].
The uptake, transport and storage of dietary vitamin A is a complex process. In the intestinal 
epithelium, dietary carotenes are converted to retinyl esters and transported to the liver via 
circulation within chylomicrons. Hepatocytes take up the chylomicrons and hydrolyze retinyl 
esters to retinyl, which is distributed from the hepatocyte to the circulation bound to the retinyl 
binding protein 4 (RBP4). HSCs absorb retinyls from the blood and convert it back to retinyl 
esters and store it in lipid droplets [13–16]. As HSC activation is trigged, cells rapidly lose their 
lipid droplets, including the vitamin A content, while transdifferentiating into myofibroblasts. As 
a consequence, vitamin A deficiency is associated with advanced liver fibrosis [13].
Vitamin A homeostasis in HSC is achieved by enzymes that esterify and hydrolyse retinyl and 
retinyl esters, respectively. Lecithin retinyl acyltransferase (LRAT) and acyl-CoA:diacylglycerol 
acyltransferase 1 (DGAT1) are responsible for retinyl esterification [12,17]. Two esterases, 
adipose triglyceride lipase/patatin-like phospholipase domain containing 2 (ATGL/PNPLA2) 
and adiponutrin (ADPN/PNPLA3), have been identified as retinyl ester hydrolases (REH) in HSC 
[18–20]. LRAT appears to be essential for hepatic retinyl esterification, as LRAT-null mice are 
prone to develop vitamin A deficiency (VAD) [21,22]. For retinyl ester hydrolysis, PNPLA3 seems 
to play a rate-limiting role, as specific PNPLA3 gene variants in humans are associated with 
hepatic  retinyl ester accumulation and serum retinyl levels(20). In contrast, ATGL-null mice 
have normal hepatic vitamin A levels implying that ATGL, while being an established REH, is 
not essential for maintaining hepatic retinoid metabolism [18]. The expression of vitamin 
A-associated enzymes, such as LRAT or PNPLA3, rapidly drops during HSC activation, along with 
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the disappearance of lipid droplets. There is a third REH, hormone-sensitive lipase (HSL), which 
is dominantly expressed in adipose tissue, but is also detected in the liver [23,24]. So far, hepatic 
HSL is reported to be expressed only in hepatocytes, where it mainly hydrolyses cholesteryl 
esters to cholesterol [24,25]. Nevertheless, the role of HSL in retinoid metabolism in HSC has 
not been studied in detail yet. 
Key factors in HSC activation and liver fibrogenesis
The extracellular matrix (ECM) is a network of proteins that provides micro-scaffolds for cells 
supporting cellular adhesion, migration, differentiation and proliferation. In the liver, ECM is 
present in the Glisson’s capsule, portal tracks, central veins and in the perisinusoidal space 
of Disse [26]. Collagens (I, III, IV, and V), fibronectin, laminin and proteoglycans are the 
predominant proteins of ECM. Collagen types I, III, and V are predominantly expressed in the 
portal and central areas, whereas collagen IV is localized mainly in basement membranes [27]. 
Fibrotic liver is highly enriched in collagen I and III (7) and about 80% is produced by HSCs, in 
particular collagen I [28].
Matrix metalloproteinase proteins (MMPs) are responsible for degradation of ECM proteins 
and, together with tissue Inhibitors of metalloproteinases (TIMPs), have fundamental roles in 
ECM remodeling during liver fibrosis and in fibrosis resolution. While activated HSC are the 
prime producers of ECM proteins, in particular collagen I, III and IV, they also express MMPs 
and TIMPs. Especially the expression of TIMP-1, is up-regulated in activated HSCs, thereby 
reducing MMP activities and promoting the accumulation of ECM (29,30). MMP-2, MMP-9, and 
MMP-13 are among highly-expressed proteins in activated HSCs. MMP-2, MMP-8 and MMP-9 
activities are significantly elevated in alcoholic liver disease and can function as serum markers 
of disease severity [31]. MMP-13 activity can be used for diagnosis of alcoholic liver cirrhosis 
[29]. Besides induced ECM production, HSC activation is characterized by elevated expression 
of alpha-smooth muscle actin (α-SMA). α-SMA is a cytoskeleton protein that has a major role in 
mobility and contractility of activated HSC [32]. The contractile force of α-SMA is stronger than 
other actin isoforms in fibroblastic cells [33].
Transforming growth factor β1 (TGF-β1) is a key mediator of HSC activation upon liver. TGF-β1 is 
a multifunctional cytokine that regulates a variety of cellular functions, including proliferation, 
differentiation, apoptosis and migration [34]. During HSC activation, TGF-β1 binds to it receptors 
and forms a complex that directly activates Smad signalling leading to overexpression of pro-




β1-induced tissue fibrosis, while Smad7 serves as a negative feedback regulator of TGF-β1/
Smad pathway and suppresses TGF-β1-mediated fibrosis [35,36]. 
PDGF is one of the most potent mitogens that stimulates HSC activation. Upon binding to its 
receptors at the membrane of HSC, PDGF triggers a signalling cascade that leads to upregulation 
of collagen synthesis, as well as  MMP-2, MMP-9 and TIMP-1, the latter of which prevents ECM 
degradation [37,38]. PDGF-B and PDGF-D are the most fibrogenic isoforms of PDGF and cause 
PDGFR-β autophosphorylation that activates the extracellular signal-regulated kinase (ERK)1/2, 
C-Jun N-terminal kinase (JNK), p38 mitogen- activated protein kinase (MAPK) and protein 
kinase (PK)B/Akt pathways leading to further proliferation and activation of HSCs and damage 
to hepatocytes [37,39]. 
Leukotrienes are pro-inflammatory mediators that increase microvascular permeability 
and causes leukocyte infiltration in inflamed areas in the fibrotic liver [40]. Leukotrienes are 
synthesized from essential fatty acids (EFA), e.g. arachidonic acid, by the enzyme arachidonate 
5-lipoxygenase, also known as 5-lipoxygenase (5-LO) (36). The inhibition of 5-LO suppresses 
renal fibrosis and progression of chronic kidney disease by preventing the production of 
leukotrienes [41].  Moreover, 5-LO, is one of the main contributors of lipid peroxidation that 
further increases tissue inflammation. Besides lipoxygenases, cyclooxygenases and cytochrome 
P450 enzymes oxidize EFAs, however, lipoxygenases contribute most prominently to the 
generation of lipid peroxides [42].
Therapeutic approaches to halt and/or reverse liver fibrosis
So far, the only effective way to stop or cure liver fibrosis is to eliminate the pathological stimulus 
that causes chronic liver damage and/or inflammation. The stimulus can be long-term exposure 
of a toxic agent, fatty diet, alcohol consumption, viral or bacterial infection. Clinical studies have 
shown that therapies aiming at elimination of the primary disease cause, e.g. antivirals in viral 
hepatitis, can regress liver fibrosis, even at advance stages [43–45]. Consequently, treatment 
against HCV infections [46–48], alcohol abstinence [49] and weight loss (50) have been reported 
to be effective to reverse liver fibrosis. 
However, in most cases of chronic liver disease, it is challenging or even currently impossible 
to eliminate the primary cause of disease. As an alternative approach, anti-inflammatory drugs 
and/or immunosuppressants are commonly used. Inflammation is a key factor that drives liver 
fibrosis and is regulated by proinflammatory and anti-inflammatory factors secreted from 
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Kupffer cells and other recruited immune cells, such as bone marrow–derived macrophages, 
neutrophils and T lymphocytes. Chronic inflammation leads to progressive hepatocyte 
damage and activation of HSCs and portal myofibroblasts [51]. Common anti-inflammatory 
drugs are corticosteroids, such as prednisone and prednisolone, and are used to suppress 
cytokine production through transcriptional regulation [52–54]. Zileuton, a 5-lipoxygenase 
inhibitor, blocks leukotriene-mediated pathways and can be considered for clinical use [55–
57]. Pentoxifylline (PTX) is another anti-inflammatory drug that suppresses Tumor Necrosis 
Factor-alfa (TNF-α) synthesis [58]. Recent studies report celecoxib [59], azathioprine [47] and 
rapamycin [60,61] as suppressors of fibrogenesis through their potent immunomodulatory 
properties. Antioxidative agents, such as taurine [47,62] and vitamin E [63] reduce oxidative 
stress and thereby suppress inflammation and resultant fibrogenesis.
HSCs develop fibrotic structures by producing abnormal extra cellular matrix (ECM) dep 
ositions, as well by secreting inflammatory cytokines that recruit immune cells to the inflamed 
area and promote local inflammation. Thus, suppressing activation and promoting apoptosis 
or senescence of HSCs are alternative approaches to halt fibrosis [64]. Inactivation of HSCs 
have been achieved in experimental models by inhibiting the principal activation mechanisms, 
including the TGF-β1/Smad- (35,36,65) and PDGF-[37] signaling pathways. Some cytokines 
and growth factors, such as Insulin-like growth factor-1 [66] and interleukin-22 [67], induce 
senescence in HSCs while IFN-α (68) and IFN-γ [10,69] are candidates for induction of HSC 
apoptosis.
Promoting hepatocyte regeneration is an important strategy to preserve liver function during 
fibrosis. Ursodeoxycholic acid (UDCA) is a hepatoprotective bile acid used for treatment of 
various chronic liver diseases, including  primary biliary cirrhosis (PBC), NAFLD and intrahepatic 
cholestasis of pregnancy (ICP) [70,71]. UDCA protects hepatocyte and cholangiocytes by 
replacing toxic bile acids, inhibition of apoptosis induced by toxic bile acids and stimulation 
of bile secretion. Hepatocyte growth factor (HGF) has been shown to reduce apoptosis and 
promote angiogenesis and liver regeneration by stimulating hepatocyte motility and mitogenesis 
[47,72,73]. Moreover, bone-marrow-derived cells and mesenchymal cells can stimulate 
proliferation of hepatocytes by producing mitogens, including HGF [72,74,75]. Although the 
impact of HGF on hepatocyte regeneration has been established in many experimental models 
of liver diseases, no clinical research is done to further develop HGF into treatment for liver 




Complementary and alternative medicine for the treatment 
of liver fibrosis 
Besides developing novel pharmaceutical compounds to target liver fibrosis, natural products 
may also hold potent anti-fibrotic properties. Melatonin is a hormone produced by the pineal 
gland and controls the sleep-wake cycle. However, melatonin can also be produced in other 
tissues, including the liver, and acts as an endogenous antioxidant [76]. Recent studies have 
revealed that a variety foods and drinks, such as vegetables, cereals, fruits, nuts, seeds, 
grapes, red wine and beer, contain considerable amounts of melatonin [77–80]. Melatonin 
is available as supplementary medication, in particular to control the day-night sleep rhythm. 
Hepatoprotective effects of melatonin have been shown in various liver diseases including, 
hepatic steatosis [81,82], hepatitis [83], fibrosis [84] and hepatocellular carcinoma [85]. The 
therapeutic effects of melatonin are mostly attributed to its ability to suppress oxidative 
stress, inflammatory signaling, hepatocyte apoptosis, neutrophil infiltration and regulation of 
profibrogenic genes [86,87]. Melatonin reduces the expression of 5-LO [88] and attenuates 
liver fibrosis in several animal models including, bile duct ligation (BDL)-induced cirrhosis [89], 
thioacetamide (TAA)-induced fibrosis [90] and carbon tetrachloride (CCl4)-induced fibrosis [91]. 
However, a direct role of melatonin on HSC activation has not been established yet.
Anti-fibrotic compounds may also be found in plants used in traditional medicine. Esculetin is 
present in many herbs, including Cortex fraxini, Artemisia capillaries, Citruslimonia, Euphorbia 
lathyris and Fraxinus rhynchophylla [92,93]. Esculetin has been used in China for treatment of 
liver and gallbladder diseases for centuries. Esculetin has anti-inflammatory and anti-tumor 
properties. It down-regulates the expression of MMP-1 in cartilage, while it also inhibits 
the production of pro-inflammatory cytokines, such as TNF-α, in co-cultured adipocytes and 
macrophages [93]. Furthermore, esculetin is a potent anti-oxidant that ameliorates mitochondrial 
damage induced by nitric oxide radicals [94], hepatic apoptosis induced by CCl4 [92] and DNA damage 
caused by lipid hydroperoxide-induced oxidative stress [95]. Moreover, esculetin has anti-hepatitis B 
virus activity (96) and inhibits 5-LO and 12-LO in leukocytes [97–99]. Other herbal compounds that 
exhibit anti-fibrotic activities include salvianolic acid B [100], oxymatrine [101], tetrandrine [102], 
glycyrrhetinic acid [103] and silymarin [104–106]. In all these examples, the pharmacological 
effects include scavenging free radicals and modulating the inflammatory pathways. In addition 
to natural compounds, there are drugs that are not preliminary developed for targeting liver 
fibrosis, yet could theoretically have such therapeutic effect. Verapamil for instance, a calcium 
channel blocker that is used to treat high blood pressure, has hepatoprotective properties. 
In NAFLD, verapamil reduces hepatic lipid droplet accumulation, insulin resistance and 
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steatohepatitis [107]. The combination of verapamil and silymarin improves liver fibrosis and 
significantly reduces mRNA and protein level of α-SMA [6]. Hydroxycarbamide, also known as 
hydroxyurea, is an antiproliferative agent, which inhibits DNA synthesis and cell cycle replication 
by blocking the enzyme ribonucleotide reductase [108]. Hydroxyurea is widely used to treat 
chronic myelogenous leukemia [109], cervical cancer [109], polycythemia [110] and sickle-cell 
disease [111]. Cellular absorption of hydroxyurea is an active transport carried out by solute care 
transporters including multi-specific organic cation transporter (OCTN1), which is expressed by 
HSCs[112]. Hydroxyurea has not yet been explored as anti-fibrotic agent.
The aim of this thesis
In this thesis, we explored the therapeutic effects of melatonin, esculetin and hydroxyurea 
on HSC activation in order to establish their potential as anti-fibrotic drugs. Additionally, we 
investigated the role of HSL in vitamin A homeostasis and activation of HSCs.
HSL is the dominant retinyl ester hydrolyser in adipose tissue. However, its expression and 
function in liver are less known and the current data is limited to its cholesterol hydrolysing 
activity in hepatocytes. Giving the fact that HSC lipid droplets abundantly accumulate retinyl 
esters, in Chapter 2, we analysed HSL expression and function in quiescent and activated HSCs. 
Numerous studies have examined the therapeutic properties of melatonin in a variety of liver 
injury models. Yet, its direct effect on HSC activation has not been explored. For possible use of 
melatonin in a treatment for liver fibrosis, it is essential to fully understand its potential impact 
on the main contributors of fibrogenesis, the activated HSC. Thus, Chapter 3 of this thesis 
explores the direct impact of melatonin on HSC activation and its 5-LO- associated inhibitory 
mechanism. 
As stated earlier, the contribution of 5-LO in promoting inflammation is well-established. We 
hypothesized that inactivating 5-LO using esculetin reduces HSC activation and ameliorates liver 
fibrosis. In Chapter 4, we therefore studied the direct effect of esculetin on HSC activation and 
proliferation in vitro and in vivo. 
In Chapter 5, we investigated the possibility of using hydroxyurea as an anti-fibrotic drug. For 
this, the effect of hydroxyurea on HSC activation and hepatocyte preservation and regeneration 
was investigated. Finally, Chapter 6 provides a summary of relevant findings and results of all 
experimental chapters followed by a general discussion that highlights possibilities for future 
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